AstraZeneca Pharma shares in focus as global parent reports Q2 results
For Q2, AstraZeneca reported revenue of $14.46 billion, ahead of the $14.12 billion estimate. Core earnings per share stood at $2.17, in line with projections, and the core operating margin remained steady at 32%.
One of the key highlights was Imfinzi, a major cancer drug, which clocked $1.46 billion in revenue, surpassing expectations of $1.34 billion.
The company declared an interim dividend of $1.03 per share and reiterated its full-year 2025 guidance, expecting high single-digit percentage growth in total revenue and low double-digit growth in core EPS.
AstraZeneca Pharma shares traded in a narrow range on July 29, moving between ₹8,865.50 and ₹9,000.00 during the session. The stock opened at ₹8,944.50, slightly above its previous close of ₹8,937.50. Despite the subdued movement, the stock remains significantly above its 52-week low of ₹6,220.00, though still below the 52-week high of ₹10,691.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 hours ago
- Business Upturn
Titagarh Rail secures contract worth Rs 1,598.55 crore for Mumbai Metro Rail Project from NCC
Titagarh Rail Systems Limited has bagged a major contract worth approximately ₹1,598.55 crore as a specialized subcontractor in the Mumbai Metro Rail Project. The Letter of Acceptance (LOA) was issued by NCC Limited on August 2, 2025. Under this high-value contract, Titagarh Rail will be responsible for the design, manufacturing, supply, installation, integration, testing, and commissioning of 108 metro coaches—comprising 18 trains with six cars each—for Mumbai Metro Line 6, which will run from Swami Samarth Nagar to Vikhroli (Eastern Express Highway). In addition to delivering the rolling stock, the contract also includes a two-year Defect Liability Maintenance Period, followed by five years of comprehensive maintenance, further expanding the company's long-term role in one of Mumbai's key metro corridors. The execution timeline for the design-build portion is 104 weeks, after which the maintenance phases will kick in. The project has been awarded by NCC Limited, a domestic entity, under the broader development plans of the Mumbai Metropolitan Region Development Authority (MMRDA). Titagarh Rail clarified that this is not a related-party transaction and no promoter or group company has any stake in NCC Limited. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Yahoo
15 hours ago
- Yahoo
What UK investors can learn from Warren Buffett's recent trades
Warren Buffett's every move is analysed under a microscope — and with good reason. As the driving force behind Berkshire Hathaway, he's created one of the most successful investment records in history. But what does his latest trading activity reveal? And are there lessons here for UK investors? While Buffett doesn't typically invest in UK-listed companies, many shares on the FTSE 100 have similar characteristics to those in his portfolio — global reach, pricing power, and consistent cash generation. In particular, two recent Berkshire Holdings — Johnson & Johnson and Constellation Brands — remind me of UK equivalents AstraZeneca and Unilever (LSE: ULVR). Here's why they may be worth considering for UK investors. A defensive pharma pick Buffett trimmed his position in healthcare giant J&J a few years ago but the logic behind owning large-cap pharma remains. Companies like these benefit from wide moats, high barriers to entry, and products people rely on regardless of the economic cycle. In that sense, AstraZeneca fits the bill. The firm has built a diverse drug portfolio and is investing in oncology, immunology, and rare diseases treatments. It also boasts impressive financials: revenue grew 12% in the second quarter of 2025 and earnings per share climbed 27%. Although the dividend yield is a modest 2.2%, the payout ratio is well-covered by earnings and has room to grow. The price-to-earnings (P/E) ratio of 19.7 may look high at first glance, but is arguably justified by the company's strong pipeline of long-term growth potential. One risk? Drug development failures and regulatory hurdles can hit revenue and sentiment hard — but for investors seeking Buffett-style defensiveness, AstraZeneca is one to consider. Always in demand Buffett has been increasing Berkshire's position in Constellation Brands recently. His love for well-known branded consumer products stems from their pricing power, consistency, and brand loyalty — traits also found in UK consumer goods giant Unilever. With household names like Dove, Hellmann's, and Persil in its portfolio, Unilever enjoys broad global exposure. In Q2 2025, turnover rose 3.3% year on year, driven by a return to volume growth. Despite inflationary pressure, it maintained operating margins above 16% — impressive for a company in this space. The 3.4 % dividend yield, backed by a payout ratio of around 75%, offers solid passive income potential. And while the share price has struggled in recent years, a forward P/E ratio of 17 suggests the worst may already be priced in. The current competitive landscape is challenging, though, and poses risks to Unilever's bottom line. Changing consumer tastes and competition from private labels could continue to weigh on profits. Over an extended period, this could threaten a dividend cut if debt piles up. Still, when looking at the bigger picture, I believe the scale and brand power of the company are enough to keep it resilient. Sustainable quality Buffett's investment principles — buy quality, hold long, ignore the noise – continue to resonate. While Berkshire Hathaway may not be snapping up FTSE 100 stocks, businesses like AstraZeneca and Unilever share many of the same strengths as his US holdings. For patient UK investors, following his philosophy might just pay off. The post What UK investors can learn from Warren Buffett's recent trades appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Mark Hartley has positions in AstraZeneca Plc and Unilever. The Motley Fool UK has recommended AstraZeneca Plc, Constellation Brands, and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 hours ago
- Yahoo
Trump threatens drug giants with crackdown over prices
Donald Trump has threatened to use 'every tool in our arsenal' to crack down on pharmaceutical giants if they fail to cut drug prices for Americans within 60 days. The president wrote to executives at 17 companies on Thursday, demanding they match their US prices for prescription drugs with the lowest price offered in other developed nations. Current prices were an 'unacceptable burden' on US families, Trump said, claiming they could be up to three times higher than in other countries. After returning to the White House earlier this year and pledging to bring down drug prices, the president claimed that 'most proposals' from the pharmaceutical industry amounted to 'more of the same', accusing firms of seeking to shift blame and requesting policies that would pave the way for handouts worths billions of dollars for the sector. 'Make no mistake: a collaborative effort towards achieving global pricing parity would be the most effective path for companies, the government, and American patients,' Trump wrote. 'But if you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices. 'Americans are demanding lower drug prices, and they need them today.' The bosses of Pfizer, AstraZeneca and GSK were among those who received the letters. GSK did not respond to requests for comment. AstraZeneca declined to comment. Pfizer said: 'Pfizer is working closely with the Trump administration and Congress on solutions that will increase access and affordability for American patients and enhance the power of the biopharmaceutical innovation ecosystem in the United States. Our discussions have been productive.' Shares in Pfizer slipped 2%, AstraZeneca fell 3.8% and GSK dropped 3.9% during afternoon trading in New York. At the heart of of Trump's proposal is a status known as 'Most Favored Nation', through which he wants to bind the cost of medications sold in the US to the lowest prices paid elsewhere. The White House is demanding that pharmaceutical companies extend this to drugs used by older people through the government-backed Medicaid health program, as well as new drugs.
